Phase II Study to Investigate Concurrent Lapatinib and Radiotherapy in Locally Advanced or Locally Recurrent Breast Cancer and the Impact on Breast Cancer Stem Cells
This phase II trial studies how well lapatinib ditosylate and radiation therapy work in treating patients with locally advanced or locally recurrent breast cancer. Lapatinib ditosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy x rays to kill tumor cells. Giving lapatinib ditosylate together with radiation therapy may be an effective treatment for breast cancer.
Stanford is not currently accepting new patients for this trial. You may want to check clinicaltrials.gov to see if other locations are recruiting.
- drug : lapatinib ditosylate
- other : laboratory biomarker analysis
- radiation : radiation therapy
Phase: Phase 2
Ages Eligible For Study:
- Patients with histologically or cytologically confirmed locally advanced breast cancer that is refractory to chemotherapy or other therapeutic agents or with a history of breast cancer with new evidence of a local recurrence (defined as a chest wall or breast recurrence and/or nodal recurrence); the diagnosis will be made based on clinical and pathologic features - Patients must be >18 years of age. - Karnofsky Performance Status (KPS) score > 70 - Patts must have normal organ function as defined below: - total bilirubin < 1.5 x institutional upper limit of normal - AST(SGOT)/ALT(SGPT) < 2.5 x institutional upper limit of normal - creatinine < 1.5 x institutional upper limit of normal - Patients must have left-ventricular ejection fraction > 50% at baseline.